We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





COVID-19 Molecular Gene Test Uses Nanosensor Technology to Detect Early and Asymptomatic Infections

By LabMedica International staff writers
Posted on 01 Feb 2022
Print article
Image: Check4 (Photo courtesy of IdentifySensors Biologics)
Image: Check4 (Photo courtesy of IdentifySensors Biologics)

A molecular gene test based on innovative nanosensor technology could reshape the future of COVID-19 diagnostic testing.

IdentifySensors Biologics (Shaker Heights, OH, USA), along with researchers at Purdue University (West Lafayette, IN, USA), has developed the new digital technology that aims to replace 50-year PCR testing for multiple infections, including COVID variants. It has finalized proof-of-concept research for its all-new COVID-19 testing method. IdentifySensors is currently in the commercialization stage with Check4, its testing platform that comprises two parts - a re-useable reader and cartridges that intend to check for several infections and pathogens. The first cartridges are intended to test for COVID and the multiple variants, and then a multiplex cartridge which will test for COVID and influenza A and B.

Check4 intends to be a highly accurate, over-the-counter self-test that is fast, accurate, and affordable. It detects early and asymptomatic infections with the accuracy of a PCR test, but without all the necessary reagents, machines, people, and delays. It is intended to avoid the limitations of current molecular tests such as enzymatic reactions, amplification, sample preservation or sample transportation, which can introduce artifacts and raise the risk of false positives. It is not an inaccurate antigen test. This electronic-based disruptive technology intends to use newly-developed nanosensors, saliva, and a user’s smartphone to disrupt the way testing is done now, and into the future. Using saliva and the user’s smartphone, results will be delivered within minutes. Check4 is easy to use and fast, accurate, and affordable. Future intended tests include MRSA, Lyme, Hep C and B, foodborne pathogens, and more.

“With COVID still raging around the globe, our test is a game-changer,” said Dr. Gregory Hummer, founder of IdentifySensors Biologics. “It’s fast, affordable and intends to provide accurate results withing minutes on your smartphone. Check4 can help us get back to living a more normal life.”

Related Links:
IdentifySensors Biologics 
Purdue University

Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Piezoelectric Micropump
Disc Pump

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.